skip to main content
Idioma:

The Therapy of SARS-CoV-2 Infection in Children

Edwards, Kathryn M

Journal of clinical medicine, 2023-12, Vol.13 (1), p.120 [Periódico revisado por pares]

Switzerland: MDPI AG

Texto completo disponível

Citações Citado por
  • Título:
    The Therapy of SARS-CoV-2 Infection in Children
  • Autor: Edwards, Kathryn M
  • Assuntos: Adults ; Clinical trials ; COVID-19 ; COVID-19 drug treatment ; Cytochrome ; Drug dosages ; Drug interactions ; Extracorporeal membrane oxygenation ; FDA approval ; Hospitalization ; Infections ; Infectious diseases ; Kinases ; Mortality ; Multisystem inflammatory syndrome in children ; Pandemics ; Pediatrics ; Review ; Severe acute respiratory syndrome coronavirus 2 ; Steroids ; Teenagers ; Ventilators
  • É parte de: Journal of clinical medicine, 2023-12, Vol.13 (1), p.120
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-3
    content type line 23
    ObjectType-Review-1
  • Descrição: The impact of SARS-CoV-2 infections in children has fortunately been lower than what has been seen in adults. However, even previously healthy children have developed severe disease, sometimes with subsequent mortality, and those who are infants or adolescents, are from racial and ethnic minority groups, or have certain chronic conditions are at higher risk of these outcomes. During the pandemic, extensive studies of therapeutic agents, including antivirals and immunomodulators, were conducted in adults. Few trials included children, and most were in older children and adolescents. Thus, the potential benefits of therapies in children must be extrapolated from adult evidence. Despite these limitations, advisory committees of the National Institute of Health (NIH), the Infectious Disease Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS) were constituted, and expert consensus guidelines were developed. This review provides a synthesis of those comprehensive recommendations for therapy in children. These address treatment during the early infectious period with antiviral agents, including remdesivir and nirmatrelvir/ritonavir, as well as treatment in the later period of immune dysregulation with corticosteroids and immunomodulators. In addition, the therapeutic approach for multisystem inflammatory syndrome in children (MIS-C), also referred to as Pediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS), is also provided.
  • Editor: Switzerland: MDPI AG
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.